REGENERON PHARMACEUTICALS, INC.REGN
REGENERON PHARMACEUTICALS, INC. Financial Overview 2021–2025
Updated Jul 10, 2026Sanofi collaboration revenue surged 29% to $5.88 billion in FY2025, driving overall top-line growth even as the company's legacy ophthalmology franchise faced fierce market competition. This momentum underscores a clear investment thesis: Regeneron has successfully navigated the loss of its pandemic windfalls to become a structurally diversified biotech powerhouse capable of funding massive internal innovation.
The company's top line contracted from a COVID-fueled peak of $16.1 billion in FY2021 to $14.34 billion in FY2025, masking the underlying expansion of its permanent commercial portfolio. To secure its next growth phase, Regeneron expanded research and development expenses to $5.85 billion in FY2025. Despite these heavy pipeline investments and a 36% collapse in legacy U.S. EYLEA sales by Q1 2026, the company easily absorbed the impact, with total quarterly revenues jumping 19% year-over-year to $3.61 billion. Operational efficiency remained intact, allowing the company to return substantial capital by initiating its first quarterly dividend of $0.88 per share and executing billions in stock repurchases throughout the year.
At the close of FY2025, the market valued the stock at $771.87, pricing the company at 18.6x its annual earnings of $41.48 per share. Supported by a massive liquidity buffer of $3.12 billion in cash and $15.40 billion in marketable securities at the end of FY2025, Regeneron retains the financial firepower necessary to defend its market share, advance its pipeline, and consistently reward shareholders.
Recent Developments (Q4 2025 and Q1 2026)
In Q1 2026, profitability contracted despite top-line expansion, with net income declining 10% year-over-year to $727.2 million. Diluted earnings per share fell to $6.75 from $7.27, heavily impacted by a 20% increase in operating expenses and a $102 million pre-tax acquired IPR&D charge. The company countered this bottom-line pressure by executing $803.2 million in share buybacks, authorizing a new $3.0 billion repurchase program, and raising its quarterly dividend to $0.94 per share.
Bulls see an attractively priced asset supported by aggressive capital returns, with shares trading at a reduced 16.5x earnings multiple based on a $686.36 closing price as of April 29, 2026. Conversely, bears point to ongoing margin compression and operational hurdles, highlighting an expected $127 million IPR&D charge in Q2 2026 and FDA approval delays for EYLEA HD’s pre-filled syringe stemming from third-party manufacturing issues.
What to watch: progress onboarding new manufacturers for EYLEA HD and Ordspono; the EPS impact of anticipated collaboration payments in Q2 2026.
Rev
$14.34B
FY2025
NI
$4.50B
FY2025
EPS
$43.07
FY2025
OCF
$4.98B
FY2025
Year-over-year comparison from 10-K annual reports
Data from SEC Company Facts
Recent SEC Filings
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jul 6, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed an 8-K report on July 6, 2026, providing a preliminary update on its expected financial results for the second quarter of 2026. The company anticipates a pre-tax acquired in-process research and development (IPR&D) charge of approximately $127 million. This charge is primarily related to up-front and opt-in payments made under various collaboration and licensing agreements. The estimated impact of this acquired IPR&D charge is a reduction of approximately $1.00 per diluted share on both Generally Accepted Accounting Principles (GAAP) and non-GAAP net income for the second quarter. Regeneron cautions that these are preliminary estimates and subject to change as financial closing procedures are completed, and actual results may differ. Investors should note that IPR&D charges are inherently unpredictable due to the uncertain nature of future collaborations and development milestones.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Shareholder Vote Results (Jun 17, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on June 17, 2026, detailing the results of its 2026 Annual Meeting of Shareholders held on June 12, 2026. The report confirms the election of Class II directors and the ratification of PricewaterhouseCoopers LLP as the independent auditor for fiscal year 2026. Additionally, shareholders provided advisory approval for executive compensation. Key outcomes include the successful election of all nominated directors, indicating strong shareholder confidence in the current board's leadership. The ratification of the auditor received substantial support, reinforcing the company's commitment to financial transparency and robust auditing practices. The advisory vote on executive compensation also passed with a significant majority, suggesting shareholder alignment with the company's compensation philosophy for its named executive officers.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 29, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on April 29, 2026, to report its financial and operating results for the first quarter ended March 31, 2026. The key details of these results are provided in a press release, which is incorporated by reference as Exhibit 99.1 to this filing. Investors should note that the information furnished under Item 2.02, including the press release, is not considered "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934 unless expressly incorporated into a future SEC filing. Investors seeking specific financial performance metrics, revenue figures, pipeline updates, or forward-looking guidance for the first quarter of 2026 should refer directly to the press release filed as Exhibit 99.1.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Apr 8, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K to disclose anticipated financial results for the first quarter of 2026. The company expects to record an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis. This charge is primarily associated with equity securities purchased and payments made under collaboration and licensing agreements. The most significant impact for investors is the expected negative effect of this IPR&D charge on both GAAP and non-GAAP net income per diluted share, estimated at $0.81 for the first quarter of 2026. It's important to note that these are preliminary estimates, subject to finalization of financial closing procedures, and actual results could differ. The company also highlighted that acquired IPR&D charges are inherently unpredictable and not typically forecasted.
REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 30, 2026)
Regeneron Pharmaceuticals, Inc. (REGN) has filed a Form 8-K on January 29, 2026, to announce its financial and operating results for the fourth quarter and full year ended December 31, 2025. The press release detailing these results is attached as Exhibit 99.1 and is incorporated by reference. Investors should refer to this press release for specific figures related to revenue, profitability, and operational performance. This filing is crucial for understanding the company's recent financial health and its trajectory heading into the new fiscal year. The information is being furnished and not deemed 'filed' under Section 18 of the Securities Exchange Act of 1934, meaning it does not automatically update previous SEC filings. Investors should consult the press release directly for comprehensive details.
View all 8-K filings →